tetano
Editor, Senior Moderator
J Clin Med
. 2022 Feb 11;11(4):937.
doi: 10.3390/jcm11040937.
Immune Response of Adult Sickle Cell Disease Patients after COVID-19 Vaccination: The Experience of a Greek Center
Christos Varelas[SUP] 1 [/SUP], Eleni Gavriilaki[SUP] 1 [/SUP], Ioanna Sakellari[SUP] 1 [/SUP], Philippos Klonizakis[SUP] 2 [/SUP], Evaggelia-Evdoxia Koravou[SUP] 1 [/SUP], Ioanna Christodoulou[SUP] 2 [/SUP], Ioulia Mavrikou[SUP] 1 [/SUP], Andreas Kourelis[SUP] 3 [/SUP], Fani Chatzopoulou[SUP] 3 [/SUP], Dimitrios Chatzidimitriou[SUP] 3 [/SUP], Tasoula Touloumenidou[SUP] 1 [/SUP], Apostolia Papalexandri[SUP] 1 [/SUP], Achilles Anagnostopoulos[SUP] 1 [/SUP], Efthimia Vlachaki[SUP] 2 [/SUP]
Affiliations
Abstract
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are essential weapons to control the spread of the coronavirus disease-19 (COVID-19) pandemic and protect immunocompromised patients. With a greater susceptibility to infection, sickle cell disease (SCD) patients are considered as "high risk" patients during the current COVID-19 pandemic. In our study, we try to determine the immune response of adult SCD patients monitored at our center after the first and second dose of the qualified mRNA vaccines available and correlate them to several disease-specific markers, as well as complement activation. The results demonstrate that the levels of neutralizing antibodies (nAbs) against SARS-CoV-2 were adequate for most patients studied after the second dose and there seemed to be a certain association with complement activation. Further studies are critical to determine the durability of this immune response and the potential benefit of a third dose.
Keywords: COVID-19; complement; hemoglobinopathies; sickle cell disease.
. 2022 Feb 11;11(4):937.
doi: 10.3390/jcm11040937.
Immune Response of Adult Sickle Cell Disease Patients after COVID-19 Vaccination: The Experience of a Greek Center
Christos Varelas[SUP] 1 [/SUP], Eleni Gavriilaki[SUP] 1 [/SUP], Ioanna Sakellari[SUP] 1 [/SUP], Philippos Klonizakis[SUP] 2 [/SUP], Evaggelia-Evdoxia Koravou[SUP] 1 [/SUP], Ioanna Christodoulou[SUP] 2 [/SUP], Ioulia Mavrikou[SUP] 1 [/SUP], Andreas Kourelis[SUP] 3 [/SUP], Fani Chatzopoulou[SUP] 3 [/SUP], Dimitrios Chatzidimitriou[SUP] 3 [/SUP], Tasoula Touloumenidou[SUP] 1 [/SUP], Apostolia Papalexandri[SUP] 1 [/SUP], Achilles Anagnostopoulos[SUP] 1 [/SUP], Efthimia Vlachaki[SUP] 2 [/SUP]
Affiliations
- PMID: 35207208
- DOI: 10.3390/jcm11040937
Abstract
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are essential weapons to control the spread of the coronavirus disease-19 (COVID-19) pandemic and protect immunocompromised patients. With a greater susceptibility to infection, sickle cell disease (SCD) patients are considered as "high risk" patients during the current COVID-19 pandemic. In our study, we try to determine the immune response of adult SCD patients monitored at our center after the first and second dose of the qualified mRNA vaccines available and correlate them to several disease-specific markers, as well as complement activation. The results demonstrate that the levels of neutralizing antibodies (nAbs) against SARS-CoV-2 were adequate for most patients studied after the second dose and there seemed to be a certain association with complement activation. Further studies are critical to determine the durability of this immune response and the potential benefit of a third dose.
Keywords: COVID-19; complement; hemoglobinopathies; sickle cell disease.